REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 27, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

April 30, 2028

Conditions
NSCLCBrain MetastasesROS1 Gene Rearrangement
Interventions
DRUG

Repotrectinib

"Repotrectinib is administered orally in capsule form, with each capsule containing size 0 hard gelatin 40 mg of the active compound in bottles containing 30 capsules.~Repotrectinib is administered orally in the form of capsules. The capsules are taken by mouth and swallowed intact (without chewing, crushing, or opening) with water or another suitable liquid."

Trial Locations (12)

8010

RECRUITING

Medizinische Universität Graz, Graz

15706

RECRUITING

Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela

24008

RECRUITING

Hospital Universitario de León, León

28007

RECRUITING

Hospital Beata María Ana, Madrid

43204

RECRUITING

Hospital Universitari Sant Joan de Reus, Reus

46010

RECRUITING

Hospital Clínico Universitario de Valencia, Valencia

48903

RECRUITING

Hospital de Cruces, Barakaldo

Unknown

RECRUITING

Medical University of Vienna, Vienna

03293

RECRUITING

Hospital de Vinalopó, Elche

03010

RECRUITING

Hospital General Universitario Dr. Balmis, Alicante

08017

RECRUITING

UOMI Cancer Center, Barcelona

08035

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

lead

MedSIR

OTHER

NCT06315010 - REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis | Biotech Hunter | Biotech Hunter